PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
17.9%
14M of 81M shares
Institutional holders
102
19 new, 16 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
1 buys · 1 sales
Net bought $101.05K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kaufman Michael A | 4,649,599 | 5.80% | 13G (passive) | Feb 26, 2026 |
| HOLD Alapkezelo Zrt. | 4,157,791 | 5.20% | 13G (passive) | Oct 14, 2026 |
| BlackRock, Inc. | 4,046,650 | 5.02% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,046,650 | 5.02% | $9.43M | +429,688 | 0.00% |
| Renaissance Technologies LLC | 1,096,000 | 1.36% | $2.55M | −128,800 | 0.00% |
| State Street Corp | 983,582 | 1.22% | $2.29M | +10,767 | 0.00% |
| Geode Capital Management, LLC | 979,995 | 1.22% | $2.28M | +114,697 | 0.00% |
| Northern Trust Corp | 922,340 | 1.14% | $2.15M | +36,892 | 0.00% |
| Vanguard Portfolio Management LLC | 510,639 | 0.63% | $1.19M | +78,154 | 0.00% |
| Stratos Wealth Partners, LTD. | 500,000 | 0.62% | $1.17M | – | 0.01% |
| Dimensional Fund Advisors LP | 493,424 | 0.61% | $1.15M | +196,581 | 0.00% |
| Goldman Sachs Group Inc | 475,922 | 0.59% | $1.11M | +224,577 | 0.00% |
| Marshall Wace, Llp | 452,757 | 0.56% | $1.05M | New | 0.00% |
| Citadel Advisors LLC | 334,227 | 0.41% | $778.75K | New | 0.00% |
| Strs Ohio | 296,100 | 0.37% | $689.91K | New | 0.00% |
| Bank of New York Mellon Corp | 232,992 | 0.29% | $542.87K | +13,685 | 0.00% |
| Main Street Financial Solutions, LLC | 214,100 | 0.27% | $498.85K | – | 0.03% |
| Bridgeway Capital Management, LLC | 189,100 | 0.23% | $440.60K | – | 0.01% |
| Hillsdale Investment Management Inc. | 185,711 | 0.23% | $432.71K | New | 0.01% |
| Charles Schwab Investment Management Inc | 180,381 | 0.22% | $420.29K | +21,070 | 0.00% |
| Millennium Management LLC | 171,535 | 0.21% | $399.68K | New | 0.00% |
| Aqr Capital Management LLC | 167,826 | 0.21% | $391.04K | +137,333 | 0.00% |
| Lazard Asset Management LLC | 165,561 | 0.21% | $385.76K | +78,944 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 14M | 17.9% | 19 / 38 | 17 / 16 | 3M | 6M |
| Q1 2026 | 100 | 17M | 20.9% | 27 / 28 | 20 / 9 | 6M | 3M |
| Q4 2025 | 83 | 15M | 18.5% | 12 / 28 | 23 / 5 | 2M | 1M |
| Q3 2025 | 77 | 14M | 17.3% | 17 / 18 | 20 / 3 | 4M | 2M |
| Q2 2025 | 63 | 12M | 14.8% | 30 / 20 | 3 / 30 | 8M | 4M |
| Q1 2025 | 63 | 8M | 10.2% | 23 / 19 | 10 / 5 | 4M | 1M |
| Q4 2024 | 45 | 4M | 5.5% | 8 / 12 | 9 / 8 | 1M | 0M |
| Q3 2024 | 45 | 3M | 4.3% | 7 / 5 | 19 / 27 | 1M | 3M |
| Q2 2024 | 66 | 6M | 7.0% | 27 / 12 | 16 / 23 | 3M | 7M |
| Q1 2024 | 63 | 10M | 12.1% | 8 / 17 | 20 / 11 | 1M | 1M |
| Q4 2023 | 66 | 10M | 12.6% | 12 / 22 | 16 / 7 | 2M | 1M |
| Q3 2023 | 61 | 9M | 11.4% | 9 / 26 | 12 / 14 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 1,932,793 | 2.40% | $4.50M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 802,533 | 1.00% | $1.90M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 695,410 | 0.86% | $1.62M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 372,499 | 0.46% | $785.97K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 248,807 | 0.31% | $579.72K | 0.04% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 215,985 | 0.27% | $511.88K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 180,314 | 0.22% | $427.34K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 180,000 | 0.22% | $419.40K | 0.28% | Jun 30, 2026 |
| Master Small Cap Index Series | 120,799 | 0.15% | $281.46K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 90,188 | 0.11% | $213.75K | 0.01% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 87,615 | 0.11% | $207.65K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund | 80,374 | 0.10% | $190.49K | 0.02% | Jul 31, 2026 |
| WisdomTree U.S. SmallCap Fund | 78,247 | 0.10% | $182.32K | 0.03% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 75,469 | 0.09% | $175.84K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 69,173 | 0.09% | $161.17K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dror Bashan | PRESIDENT AND CEO, Director | 2,532,934 | 3.14% | Sep 4, 2026 |
| Yaron Naos | Sr. VP & COO | 232,929 | 0.29% | Sep 4, 2026 |
| Gilad Mamlok | Sr. VP and CFO | 3,631 | 0.00% | Apr 27, 2026 |
| Eyal Rubin | Sr. VP and CFO | 660,909 | 0.82% | Nov 5, 2024 |
| Aharon Schwartz | Director | 310,500 | 0.39% | Sep 9, 2026 |
| Amos Bar-Shalev | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Zvi Shmuel Ben | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Eliot Forster | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Christian Elze | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Gwen A. Melincoff | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Pol F. Boudes | Director | 7,540 | 0.01% | Sep 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dror Bashan PRESIDENT AND CEO, Director | Dec 19, 2025 | Buy | +56,000 | $1.81 | $101.36K | 188,516 |
| Amos Bar-Shalev Director | Nov 18, 2025 | Sale | −168 | $1.87 | $314 | 0 |
| Pol F. Boudes Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Christian Elze Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Yaron Naos Sr. VP, Operations | Sep 3, 2025 | Award | +25,000 | – | – | 225,817 |
| Amos Bar-Shalev Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Aharon Schwartz Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Gwen A. Melincoff Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Zvi Shmuel Ben Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Eliot Forster Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Dror Bashan PRESIDENT AND CEO, Director | Sep 3, 2025 | Award | +195,000 | – | – | 2,344,418 |
| Aharon Schwartz Director | Jun 10, 2025 | Buy | +129,000 | $1.60 | $206.40K | 303,000 |
| Eyal Rubin Sr. VP and CFO | Sep 23, 2024 | Award | +90,909 | – | – | 660,909 |
| Eyal Rubin Sr. VP and CFO | Sep 23, 2024 | Award | +99,010 | – | – | 669,010 |
| Dror Bashan PRESIDENT AND CEO, Director | Apr 1, 2024 | Award | +263,960 | – | – | 2,149,418 |
| Dror Bashan PRESIDENT AND CEO, Director | Oct 19, 2023 | Buy | +48,387 | $1.40 | $67.74K | 116,387 |
| Dror Bashan PRESIDENT AND CEO, Director | Oct 19, 2023 | Buy | +16,129 | $1.41 | $22.74K | 132,516 |
| Eyal Rubin Sr. VP and CFO | Aug 15, 2023 | Award | +201,903 | – | – | 570,000 |
| Dror Bashan President and CEO, Director | Aug 15, 2023 | Award | +800,000 | – | – | 1,885,458 |
| Yael Hayon VP, Research & Development | Aug 15, 2023 | Award | +35,115 | – | – | 35,115 |
| Yaron Naos Sr. VP, Operations | Aug 15, 2023 | Award | +187,344 | – | – | 200,817 |
| Aharon Schwartz Director | Jan 3, 2023 | Buy | +110,000 | $1.42 | $156.20K | 174,000 |
| Dror Bashan President and CEO, Director | Apr 11, 2022 | Buy | +68,000 | $1.50 | $102.00K | 68,000 |
| Eyal Rubin Sr. VP and CFO | Feb 25, 2022 | Award | +121,951 | – | – | 368,097 |
| Dror Bashan President and CEO, Director | Feb 25, 2022 | Award | +637,531 | – | – | 1,085,458 |
| Dan Oren 10% owner | Jun 3, 2021 | Sale | −857,506 | $2.25 | $1.93M | 3,637,314 |
| Dan Oren 10% owner | Jun 2, 2021 | Sale | −61,211 | $2.56 | $156.70K | 4,494,820 |
| Eyal Rubin Sr. VP and CFO | Aug 11, 2020 | Award | +246,146 | – | – | 246,146 |
| Dror Bashan President and CEO, Director | Aug 11, 2020 | Award | +447,927 | – | – | 447,927 |
| Eyal Rubin Sr. VP and CFO | Aug 11, 2020 | Award | +246,146 | – | – | 246,146 |
| Dror Bashan President and CEO, Director | Aug 11, 2020 | Award | +447,927 | – | – | 447,927 |
| Aharon Schwartz Director | Apr 7, 2020 | Buy | +64,000 | $2.43 | $155.52K | 64,000 |
| Moshe Manor President & CEO, Director | May 16, 2017 | Buy | +50,000 | $0.81 | $40.50K | 50,000 |
| Capital Management LLC Camber 10% owner | Dec 2, 2016 | Sale | −2,500,000 | $0.32 | $800.00K | 10,775,000 |
| Yoseph Shaaltiel Executive VP, R&D | Sep 15, 2016 | Option exercise | +122,162 | – | – | 585,916 |
| Yossi Maimon Vice President & CFO | Dec 14, 2015 | Buy | +10,000 | $0.78 | $7.80K | 10,000 |
| Capital Management LLC Camber 10% owner | Oct 19, 2015 | Buy | +423 | $1.03 | $436 | 13,275,000 |
| Capital Management LLC Camber 10% owner | Oct 19, 2015 | Buy | +4,000,000 | $1.00 | $4.00M | 13,274,577 |
| Zeev Bronfeld Director | Oct 2, 2014 | Other | +324,372 | – | – | 2,162,481 |
| Zeev Bronfeld Director | Oct 2, 2014 | Other | −1,509,948 | – | – | 0 |
| Zeev Bronfeld Director | Sep 16, 2014 | Other | +1,838,109 | – | – | 1,838,109 |
| Zeev Bronfeld Director | Sep 16, 2014 | Other | −8,556,371 | – | – | 1,509,948 |
| Ltd Bio-Cell 10% owner | Sep 16, 2014 | Other | −8,556,371 | – | – | 1,509,948 |
| Ltd Bio-Cell 10% owner | Aug 13, 2014 | Sale | −4,400,000 | $2.47 | $10.87M | 10,066,319 |
| Zeev Bronfeld Director, 10% owner | Aug 13, 2014 | Sale | −4,400,000 | $2.47 | $10.87M | 10,066,319 |
| Alfred Akirov Director | Aug 15, 2013 | Sale | −2,330 | $5.07 | $11.81K | 4,915,383 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −5,000 | $5.08 | $25.40K | 4,917,713 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −100,000 | $5.05 | $505.00K | 4,927,713 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −5,000 | $5.07 | $25.35K | 4,922,713 |
| Alfred Akirov Director | Mar 12, 2013 | Sale | −10,000 | $5.70 | $57.00K | 5,027,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −10,000 | $5.72 | $57.20K | 5,042,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −3,000 | $5.75 | $17.25K | 5,052,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −300 | $5.79 | $1.74K | 5,055,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −5,000 | $5.71 | $28.55K | 5,037,711 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −1,898 | $5.95 | $11.29K | 5,056,013 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −2,500 | $5.92 | $14.80K | 5,057,911 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −2,500 | $5.91 | $14.78K | 5,060,411 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −10,000 | $5.82 | $58.20K | 5,062,911 |
| Alfred Akirov Director | Mar 7, 2013 | Sale | −3,435 | $5.73 | $19.68K | 5,072,911 |
| Alfred Akirov Director | Mar 7, 2013 | Sale | −5,000 | $5.71 | $28.55K | 5,076,346 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.